FDA product approval
not established. No approval for this exact marketed preparation or claimed wellness indication is established in this source set.
Research compound · compound · checked 2026-10-09
Orexin A (Hypocretin-1) is listed here as a compound. Hypothalamic neuropeptide involved in sleep and wake signaling. Status was checked 2026-10-09. This card reports cited facts. It does not tell you to use Orexin A (Hypocretin-1) or how much to take.
Last checked Oct 9, 2026 by PepBear. Not medical advice.
Other names in the library: hypocretin-1, orexin A, Orexin A Spray, Orexin A. Evidence describes the named substance, not a quality certification or equivalence assessment of commercial stock. Listed sizes: no listed milligram sizes in the vendor file. A seller title is a listing. It does not prove the vial matches a paper.
Hypothalamic neuropeptide involved in sleep and wake signaling.
FDA product approval
not established. No approval for this exact marketed preparation or claimed wellness indication is established in this source set.
Compounding
not established. Legal compounding eligibility is not established here. Sale or a supplement label does not establish eligibility.
Research
investigational. 14 subjects with narcolepsy and cataplexy in a blinded crossover study.
Sport
unknown. Not individually verified against current sport rules. Check the exact ingredients with your sport authority.
We mark the cited papers as C for 14 subjects with narcolepsy and cataplexy in a blinded crossover study. and Researchers assessed sleep, wakefulness and attention after intranasal orexin-A.. Very small disease-specific experiment; it does not establish a cognitive or energy benefit in healthy users. Researchers assessed sleep, wakefulness and attention after intranasal orexin-A. Very small disease-specific experiment; it does not establish a cognitive or energy benefit in healthy users. Risks on the record: Human safety for this exact preparation is incompletely characterized. A lack of reported problems does not establish safety.
We mark the cited papers as C. That is our label for how strong those papers are. It does not say the compound works.
human-trial
Researchers assessed sleep, wakefulness and attention after intranasal orexin-A.
14 subjects with narcolepsy and cataplexy in a blinded crossover study. Very small disease-specific experiment; it does not establish a cognitive or energy benefit in healthy users.
The catalog does not record a single hour value. No verified human estimate for this exact preparation is supplied. A half-life is not a treatment schedule.
Half-life on file: no single hour value. No verified human estimate for this exact preparation is supplied. A half-life is not a treatment schedule. Follow the label on the vial you hold. This page does not set a throw-away date after you add water.
This card has no units chart until a milligram size is listed.
People using PepBear often log: Exact product identity, formulation, dated label and any clinician-directed observations. Record symptoms and changes alongside other medicines, sleep and activity; observations do not establish causation.
not established. No approval for this exact marketed preparation or claimed wellness indication is established in this source set.
The calculator turns numbers you type into U-100 units. Trial or label amounts stay as cited facts.
Discuss the evidence and unresolved identity or safety questions with a licensed clinician. This entry provides no treatment instructions. Not medical advice. PepBear does not pick a dose, a cycle, or a seller.